Zobrazeno 1 - 9
of 9
pro vyhledávání: '"John M. Warrington"'
Autor:
Amanda Heard, Jack H. Landmann, Ava R. Hansen, Alkmini Papadopolou, Yu-Sung Hsu, Mehmet Emrah Selli, John M. Warrington, John Lattin, Jufang Chang, Helen Ha, Martina Haug-Kroeper, Balraj Doray, Saar Gill, Marco Ruella, Katharina E. Hayer, Matthew D. Weitzman, Abby M. Green, Regina Fluhrer, Nathan Singh
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
Loss of surface CD19 expression by leukemic cells leads to resistance and relapse to CD19-targeted CAR-T therapies. Here the authors show that loss of SPPL3 in malignant B cells results in hyperglycosylation of CD19.
Externí odkaz:
https://doaj.org/article/0f7c94a068e44180b9af36e2164d17d4
Publikováno v:
Cell Reports Medicine, Vol 1, Iss 3, Pp 100036- (2020)
Summary: Here we propose a SARS-CoV-2 vaccine design concept based on identification of highly conserved regions of the viral genome and newly acquired adaptations, both predicted to generate epitopes presented on major histocompatibility complex (MH
Externí odkaz:
https://doaj.org/article/97c9aa059a124d5dbb6e002449261e5d
Autor:
Mehmet Emrah Selli, Jack Landmann, Marina Terekhova, John Lattin, Amanda Heard, Yu-Sung Hsu, Tien-Ching Chang, Ju-fang Chang, John M Warrington, Helen Ha, Natalie L Kingston, Graham Hogg, Michael Slade, Melissa M Berrien-Elliott, Mark Foster, Samantha Kersting-Schadek, Agata Gruszczynska, David DeNardo, Todd A Fehniger, Maxim Artyomov, Nathan Singh
Publikováno v:
bioRxiv
T cells engineered to express chimeric antigen receptors (CARs) targeting CD19 have demonstrated impressive activity against relapsed or refractory B cell cancers yet fail to induce durable remissions for nearly half of patients treated. Enhancing th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa7a2644e8cc9f45e51569d91c0b648e
https://doi.org/10.1101/2023.01.26.525725
https://doi.org/10.1101/2023.01.26.525725
Autor:
Kristopher R. Bosse, Laurence C. Eisenlohr, Nikolaos G. Sgourakis, Nathan M. Kendsersky, Rasika Premaratne, David Groff, Helena Shen, Daniel Martinez, Sarvind Tripathi, Tiffany Noel, John M. Maris, Rebecca Weisberg, Son Nguyen, Jugmohit S. Toor, Mark Yarmarkovich, John M. Warrington, Nicole L. Church, Stefan Stevanovic, Quinlen F. Marshall, Ben R. Kiefel, Erin Runbeck, Hau Truong, Alvin Farrel, Wei Li, Amber K. Weiner, Molly Christie, Moreno Di Marco, Dimiter S. Dimitrov
Publikováno v:
Nature
The majority of oncogenic drivers are intracellular proteins, thus constraining their immunotherapeutic targeting to mutated peptides (neoantigens) presented by individual human leukocyte antigen (HLA) allotypes1. However, most cancers have a modest
Publikováno v:
Cell Reports Medicine
Cell Reports Medicine, Vol 1, Iss 3, Pp 100036-(2020)
Cell Reports Medicine, Vol 1, Iss 3, Pp 100036-(2020)
Summary Here we propose a SARS-CoV-2 vaccine design concept based on identification of highly conserved regions of the viral genome and newly acquired adaptations, both predicted to generate epitopes presented on MHC class I and II across the vast ma
Publikováno v:
SSRN
bioRxiv
bioRxiv
Here we propose a vaccination strategy for SARS-CoV-2 based on identification of both highly conserved regions of the virus and newly acquired adaptations that are presented by MHC class I and II across the vast majority of the population, are highly
Publikováno v:
Best Practice & Research Clinical Haematology. 34:101304
Chimeric antigen receptor (CAR) T cells have revolutionized the management of B cell malignancies. These synthetic molecules are composed of peptide fragments from several distinct immune cell proteins and link highly-specific antigen recognition wit
Autor:
John M. Maris, Pete Smith, Quinlen F. Marshall, Wei Li, Nikolaos G. Sgourakis, John M. Warrington, Moreno Di Marco, Stefan Stevanovic, Mark Yarmarkovich, Helena Shen, Matt Beasley, Dimiter S. Dimitrov
Publikováno v:
Cancer Research. 81:1493-1493
Background: The MHC presents a snapshot of the intracellular proteome for surveillance by T cells, including peptides from mutated proteins (neoantigens) and nonmutated but aberrantly expressed proteins. Though peptides derived from nonmutated oncopr
Publikováno v:
Clinical Cancer Research. 26:PO-049
The current SARS-CoV-2 pandemic has precipitated an urgent need for a safe and effective vaccine to be developed and deployed in a highly accelerated timeframe as compared to standard vaccine development processes. Upfront selection of epitopes most